BiomX Inc. (NYSE: PHGE), a microbiome company developing both natural and engineered phage therapies that target specific pathogenic bacteria, today disclosed pre-clinical data from its acne program, originally planned to be presented at the Annual Meeting of the American Academy of Dermatology (AAD) on March 20, 2020 before the conference was canceled due to ongoing COVID-19 pandemic concerns. The pre-clinical data can be found on the AAD’s website as well as the Company’s website.
BiomX is developing BX001, its lead product candidate, to modify the appearance of acne prone skin. BX001 is a topically administered gel comprised of a cocktail of naturally occurring phage targeting Cutibacterium acnes (C. acnes), a bacterium implicated in the pathophysiology of acne vulgaris. The pre-clinical data disclosed include in vitro results demonstrating BX001’s activity against C. acnes, including antibiotic resistant clinical isolates of C. acnes, and BX001’s ability to penetrate biofilm, a matrix secreted by the bacteria which makes them less accessible to antibiotics. Phase 1 data from a cosmetic clinical study of BX001 in acne prone skin are expected by the end of the first quarter of 2020.
Bacteriophage, or phage, are viruses that target bacteria and are considered inert to mammalian cells. Phage are designed to target and kill specific bacterial species or strains without disrupting other bacteria or the healthy microbiota. All of BiomX’s phage-based product candidates derive from its proprietary platform, which is first used to discover and validate the association of specific bacterial strains with human diseases or conditions, and is then used to develop rationally-designed phage combinations ("cocktails") of naturally occurring or synthetic phage to target pathogenic bacteria. The phage cocktails contain multiple phage with complementary functions optimized through in vitro and in vivo testing.
BiomX is a clinical-stage biotechnology company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and colorectal cancer (CRC). BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.
Safe Harbor Language
This press release contains certain "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "target," "believe," "expect," "will," "may," "anticipate," "estimate," "would," "positioned," "future," and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on BiomX management’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. You should review additional disclosures we make in our filings with the Securities and Exchange Commission (the "SEC"), which are available on the SEC’s website at www.sec.gov.
Chief Business Officer
+972 (54) 222-8901
Stern IR, Inc.
+1 (212) 362-1200